LAUSR

Background: One of the main severe asthma phenotype is the “severe eosinophilic” or “eosinophilic refractory” asthma, for which novel biologic agents are emerging as therapeutical options. In this context, blood eosinophils count are one of the most reliable biomarker. Objective: The aim of our study is to evaluate the performance of a point-of-care peripheral blood counter in a clinical setting of severe asthmatics. Methods: Seventy-six patients with severe asthma were evaluated, for blood cells count, by both a point-of-care and a standard analyser. Results: A significant correlation between blood eosinophils assessed by the two devices was found (R2=0.854, p Conclusions: The results of our study contribute to validate a point-of-care device to assess blood eosinophils and open the possibility to use this technology for the management of severe asthma management.